An oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients.
Kevin H. Hall, PharmD, BCOP
Advertisement
Articles by Kevin H. Hall, PharmD, BCOP
Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
Advertisement
Latest Updated Articles
How to Decide Which DLBCL Patients Should Receive CNS ProphylaxisPublished: June 15th 2018 | Updated:
Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and ConstipationPublished: March 13th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
5
